biostudies-literatureUnknown38(9)Syed YYRTS,S/AS01 (Mosquirix^®) is a vaccine against malaria caused by <i>Plasmodium falciparum</i>. In a phase 3 trial, RTS,S/AS01 showed vaccine efficacy against clinical malaria, severe malaria and malaria hospitalization, with an acceptable safety and tolerability profile, in children aged 6 weeks to 17 months; the vaccine efficacy was greater in children than in infants and waned over time. In another phase 3 trial, RTS,S/AS01 was noninferior to seasonal malaria chemoprevention in children. WHO recommends a 4-dose schedule of RTS,S/AS01 for the prevention of <i>P. falciparum</i> malaria in children from 5 months of age living in regions with moderate to high malaria transmission, with an optional 5-dose schedule for areas with highly seasonal malaria transmission. First results froDrugs & therapy perspectives : for rational drug selection and use373-381https://www.ebi.ac.uk/biostudies/studies/S-EPMC9449949biostudies-literatureRTS,S/AS01 malaria vaccine (Mosquirix^®): a profile of its use.PMC9449949Syed YYfalseRTS,S/AS01 malaria vaccine (Mosquirix^®): a profile of its use.RTS,S/AS01 (Mosquirix^®) is a vaccine against malaria caused by <i>Plasmodium falciparum</i>. In a phase 3 trial, RTS,S/AS01 showed vaccine efficacy against clinical malaria, severe malaria and malaria hospitalization, with an acceptable safety and tolerability profile, in children aged 6 weeks to 17 months; the vaccine efficacy was greater in children than in infants and waned over time. In another phase 3 trial, RTS,S/AS01 was noninferior to seasonal malaria chemoprevention in children. WHO recommends a 4-dose schedule of RTS,S/AS01 for the prevention of <i>P. falciparum</i> malaria in children from 5 months of age living in regions with moderate to high malaria transmission, with an optional 5-dose schedule for areas with highly seasonal malaria transmission. First results fro2022-01-01T00:00:00Z20222026-05-28T05:40:44.321Z2025-02-19T04:38:13.246ZS-EPMC94499493609326510.1007/s40267-022-00937-3